Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Blood（2022）
关键词
irreversible btk inhibitor,primary/secondary vitreoretinal lymphoma,primary/secondary cns lymphoma,gb5121,brain-penetrant
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要